Jiedu Tongluo Tiaogan Formula Modulates Glycolipid Metabolism in Type 2 Diabetes via Pyroptosis: Network Pharmacology and In Vivo Analysis
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Su Jing und 8 weiteren Autor:innen. Beteiligte Einrichtung: Changchun University of Chinese Medicine, Changchun, China. Hauptthemen laut MEDLINE: Pyroptosis, Diabetes Mellitus, Type 2, Drugs, Chinese Herbal, Glycolipids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Natural Science Foundation of Jilin Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is characterized by pancreatic β‐cell dysfunction and insulin resistance, with pyroptosis emerging as a key contributor to β‐cell loss. Jiedu Tongluo Tiaogan Formula (JTTF), a traditional Chinese medicine (TCM), has shown clinical efficacy in T2DM management, but its mechanism linking pyroptosis remains unexplored. This study integrates UPLC‐MS/MS, network pharmacology, and in vivo experiments to elucidate JTTF's anti‐diabetic mechanisms. UPLC‐MS/MS identified 441 compounds in JTTF, predominantly alkaloids, flavonoids, phenols, and terpenoids. Network pharmacology revealed JTTF's multi‐target effects on T2DM‐associated pyroptosis, particularly via the NLRP3/Caspase‐1/GSDMD pathway. In diabetic mice, JTTF dose‐dependently reduced fasting blood glucose, insulin resistance, and dyslipidemia, while restoring pancreatic β‐cell morphology. Mechanistically, JTTF suppressed NLRP3 inflammasome activation, downregulated Caspase‐1 and GSDMD expression, and attenuated IL‐1β/IL‐18 release. Notably, this study provides the first evidence of JTTF's anti‐pyroptotic effects in T2DM, highlighting its unique ability to modulate glycolipid metabolism and inflammatory cell death concurrently. These findings underscore JTTF's translational promise for preserving β‐cell function and suggest future exploration of non‐classical pyroptosis pathways. Our work bridges traditional medicine and molecular pharmacology, paving the way for clinical trials and integrative T2DM therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Changchun University of Chinese Medicine, Changchun, China.
- Jilin Hospital of Integrated Traditional Chinese and Western Medicine, Jilin, China.
ORCID-Profile: Jin Meiying
Förderung
- Natural Science Foundation of Jilin Province
Zitieren
APA
Jing, S., Zhenhai, C., Xiao, H., Chunhan, L., Wanlin, W., Xuting, S., Han, Y., Xiaoyu, Z., & Meiying, J. (2025). Jiedu Tongluo Tiaogan Formula Modulates Glycolipid Metabolism in Type 2 Diabetes via Pyroptosis: Network Pharmacology and In Vivo Analysis. Biomedical Chromatography. https://doi.org/10.1002/bmc.70077
Vancouver
Jing S, Zhenhai C, Xiao H, Chunhan L, Wanlin W, Xuting S, et al. Jiedu Tongluo Tiaogan Formula Modulates Glycolipid Metabolism in Type 2 Diabetes via Pyroptosis: Network Pharmacology and In Vivo Analysis. Biomedical Chromatography. 2025. doi:10.1002/bmc.70077
BibTeX
@article{Jing2025,
author = {Jing, Su and Zhenhai, Cui and Xiao, Han and Chunhan, Li and Wanlin, Wang and Xuting, Song and Han, Yu and Xiaoyu, Zhuang and Meiying, Jin},
title = {Jiedu Tongluo Tiaogan Formula Modulates Glycolipid Metabolism in Type 2 Diabetes via Pyroptosis: Network Pharmacology and In Vivo Analysis},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70077}
}
EUVIMED